Asset Details
Do you wish to reserve the book?
Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation
Do you wish to request the book?
Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation
2025
Overview
The resolution of the recent COVID-19 pandemic still requires attention, since the consequences of having suffered the infection, even in mild cases, are associated with several acute and chronic pathological conditions referred to as post-COVID syndrome (PCS). PCS often manifests with pulmonary disease and, in up to 9% of cases, a more serious complication known as post-COVID-19 pulmonary fibrosis (PC19-PF), which has a similar clinical course as idiopathic pulmonary fibrosis (IPF). Generating knowledge to provide robust evidence about the clinical benefits of different therapeutic strategies to treat the pulmonary effects of PCS can provide new insights to amplify therapeutic options for these patients. We present evidence found after a scoping review, following extended PRIMSA guidelines, for the use of immunomodulators in pulmonary PCS. We start with a brief description of the immunomodulatory properties of the relevant drugs, their clinically proven efficacy for viral infections and chronic inflammatory conditions, and their use during the COVID-19 pandemic. We emphasize the need for well-designed clinical trials to improve our understanding the physiopathology of pulmonary PCS and PC19-PF and also to determine the efficacy and safety of candidate treatments.
Publisher
MDPI AG,MDPI
Subject
/ COVID-19
/ Enzymes
/ Humans
/ Idiopathic Pulmonary Fibrosis - drug therapy
/ Idiopathic Pulmonary Fibrosis - immunology
/ Immunologic Factors - therapeutic use
/ Immunomodulating Agents - therapeutic use
/ Lungs
/ Pulmonary Fibrosis - drug therapy
/ Pulmonary Fibrosis - etiology
/ Pulmonary Fibrosis - immunology
/ Respiratory distress syndrome
/ Review
